The primary objectives of this study are to determine the safety and efficacy of Amivita, a
compound of amino acids and vitamines in patients with Amyotrophic lateral sclerosis
(ALS)ALS. The secondary objectives are to measure quality of life before and during
intervention. This is a self-controlled clinical trial. Twenty patients in our ALS center who
are already receiving riluzole or other treatments but the condition is worsening will
receive treatment for 1o months. The evaluating investigators will be blinded to treatment
assignment. Primary outcome measures will be adverse events, the ALS Functional Rating
Scale-Revised (ALSFRS-R), and survival. Subjects will also be assessed at enrollment and at
study end for weight loss, forced vital capacity (FVC), quality of life and grip strength.